Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 10, 2021 16:01 ET | Source: Crinetics Pharmaceuticals, Inc.

Crinetics Pharmaceuticals’ Oral ACTH Antagonist, CRN04894, Demonstrates Pharmacologic Proof-of-Concept with Dose-Dependent Cortisol Suppression in Single Ascending Dose Portion of Phase 1 Study

CRN04894 Phase 1 Study Progressing to Multiple Ascending Dose Cohorts Management Hosting Webcast and Conference Call Today to Discuss Findings at 4:30 p.m. Eastern Time SAN DIEGO, Aug. 10,...
March 30, 2021 16:05 ET | Source: Crinetics Pharmaceuticals, Inc.

Crinetics Pharmaceuticals Announces 2021 Clinical Plans and Reports Fourth Quarter and Full Year 2020 Financial Results

Advancing paltusotine into a Phase 3 program for acromegaly following an FDA meeting Phase 1 clinical proof-of-concept data for CRN04894 and CRN04777 expected in 1H 2021 and mid-2021, respectively ...
March 22, 2021 07:10 ET | Source: Crinetics Pharmaceuticals, Inc.

Crinetics Pharmaceuticals Pipeline Progress on Display at ENDO 2021

SAN DIEGO, March 22, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of...
September 04, 2020 07:30 ET | Source: Crinetics Pharmaceuticals, Inc.

Crinetics Pharmaceuticals Provides New Data from Paltusotine and ACTH Antagonist Development Programs at European Congress of Endocrinology

SAN DIEGO, Sept. 04, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...
February 19, 2020 07:30 ET | Source: Crinetics Pharmaceuticals, Inc.

Crinetics Pharmaceuticals to Participate in SVB Leerink Global Healthcare Conference

SAN DIEGO, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...
January 08, 2020 07:30 ET | Source: Crinetics Pharmaceuticals, Inc.

Crinetics Pharmaceuticals to Present at J.P. Morgan Healthcare Conference

SAN DIEGO, Jan. 08, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...
November 26, 2019 16:05 ET | Source: Crinetics Pharmaceuticals, Inc.

Crinetics Pharmaceuticals to Participate in the Piper Jaffray Healthcare Conference

SAN DIEGO, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...
November 12, 2019 16:04 ET | Source: Crinetics Pharmaceuticals, Inc.

Crinetics Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update

SAN DIEGO, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...
March 18, 2019 07:30 ET | Source: Crinetics Pharmaceuticals, Inc.

Crinetics Pharmaceuticals Appoints Gina Ford, RPh, MBA, as Vice President, Corporate Strategy and Commercial Planning

SAN DIEGO, March 18, 2019 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...
November 20, 2018 07:30 ET | Source: Crinetics Pharmaceuticals, Inc.

Crinetics Pharmaceuticals to Participate in Piper Jaffray 30th Annual Healthcare Conference

SAN DIEGO, Nov. 20, 2018 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...

Next Page keyboard_arrow_right